TY - JOUR
T1 - Flash drug release from nanoparticles accumulated in the targeted blood vessels facilitates the tumour treatment
AU - Zelepukin, Ivan V.
AU - Griaznova, Olga Yu
AU - Shevchenko, Konstantin G.
AU - Ivanov, Andrey V.
AU - Baidyuk, Ekaterina V.
AU - Serejnikova, Natalia B.
AU - Volovetskiy, Artur B.
AU - Deyev, Sergey M.
AU - Zvyagin, Andrei V.
N1 - Copyright © 2022, The Author(s). Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.
PY - 2022/12
Y1 - 2022/12
N2 - Tumour microenvironment hinders nanoparticle transport deep into the tissue precluding thorough treatment of solid tumours and metastatic nodes. We introduce an anticancer drug delivery concept termed FlaRE (Flash Release in Endothelium), which represents alternative to the existing approaches based on enhanced permeability and retention effect. This approach relies on enhanced drug-loaded nanocarrier accumulation in vessels of the target tumour or metastasised organ, followed by a rapid release of encapsulated drug within tens of minutes. It leads to a gradient-driven permeation of the drug to the target tissue. This pharmaceutical delivery approach is predicted by theoretical modelling and validated experimentally using rationally designed MIL-101(Fe) metal-organic frameworks. Doxorubicin-loaded MIL-101 nanoparticles get swiftly trapped in the vasculature of the metastasised lungs, disassemble in the blood vessels within 15 minutes and release drug, which rapidly impregnates the organ. A significant improvement of the therapeutic outcome is demonstrated in animal models of early and late-stage B16-F1 melanoma metastases with 11-fold and 4.3-fold decrease of pulmonary melanoma nodes, respectively.
AB - Tumour microenvironment hinders nanoparticle transport deep into the tissue precluding thorough treatment of solid tumours and metastatic nodes. We introduce an anticancer drug delivery concept termed FlaRE (Flash Release in Endothelium), which represents alternative to the existing approaches based on enhanced permeability and retention effect. This approach relies on enhanced drug-loaded nanocarrier accumulation in vessels of the target tumour or metastasised organ, followed by a rapid release of encapsulated drug within tens of minutes. It leads to a gradient-driven permeation of the drug to the target tissue. This pharmaceutical delivery approach is predicted by theoretical modelling and validated experimentally using rationally designed MIL-101(Fe) metal-organic frameworks. Doxorubicin-loaded MIL-101 nanoparticles get swiftly trapped in the vasculature of the metastasised lungs, disassemble in the blood vessels within 15 minutes and release drug, which rapidly impregnates the organ. A significant improvement of the therapeutic outcome is demonstrated in animal models of early and late-stage B16-F1 melanoma metastases with 11-fold and 4.3-fold decrease of pulmonary melanoma nodes, respectively.
UR - http://www.scopus.com/inward/record.url?scp=85141978554&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-34718-3
DO - 10.1038/s41467-022-34718-3
M3 - Article
C2 - 36376302
AN - SCOPUS:85141978554
SN - 2041-1723
VL - 13
SP - 1
EP - 15
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 6910
ER -